GlassScriptPhysician profile
Sharon M Dowell
NPI 1225214463
$73,047.64
in general payments reported to CMS, 2019-2025
41 companies · $10K in 2025
The $10K reported for 2025 was more than what 90% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $9,857 · 2021: $800 · 2022: $23K · 2023: $736 · 2024: $1,046 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,764 · Food and Beverage: $3,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,764.00 |
| Food and Beverage | $3,290.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $16,725.30 | 2019-2023 | Krystexxa |
| Abbvie INC. | $16,523.10 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $14,563.38 | 2019-2025 | Tremfya, Simponi Aria, Rybrevant |
| Ucb, INC. | $10,319.54 | 2019-2025 | Bimzelx |
| Amgen INC. | $5,882.82 | 2019-2025 | Blincyto, Enbrel, Evenity |
| Cardinal Health 108 LLC | $2,420.78 | 2019 | |
| Janssen Research & Development, LLC | $1,701.96 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $856.52 | 2019 | |
| Glaxosmithkline, LLC. | $710.30 | 2019-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $677.64 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $271.37 | 2022-2025 | Imfinzi, Saphnelo |
| Novartis Pharmaceuticals Corporation | $260.87 | 2019-2025 | |
| Genentech USA, INC. | $225.06 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $208.33 | 2019-2025 | Libtayo |
| Sobi, INC | $206.43 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $193.09 | 2020-2025 | Acthar |
| Merck Sharp & Dohme LLC | $189.15 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $187.84 | 2019-2025 | |
| Csl Behring | $119.97 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $90.68 | 2024-2025 | Orencia, Sotyktu |
| Exelixis INC. | $84.07 | 2023-2025 | Cabometyx |
| Lilly USA, LLC | $76.57 | 2024-2025 | Taltz |
| Alexion Pharmaceuticals, INC. | $65.24 | 2022-2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.82 | 2023-2024 | Ofev, Cyltezo |
| Genzyme Corporation | $47.91 | 2025 | |
| Incyte Corporation | $42.41 | 2024-2025 | Jakafi |
| Aveo Pharmaceuticals, INC. | $41.39 | 2023 | Fotivda |
| Phadia US INC. | $38.83 | 2021 | |
| Eisai INC. | $37.61 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.96 | 2024 | Advate, Ninlaro |
| Sumitomo Pharma America, INC. | $33.83 | 2025 | Orgovyx |
| Actelion Pharmaceuticals US, INC. | $24.04 | 2023 | Opsumit |
| Tersera Therapeutics LLC | $22.01 | 2023 | Xermelo |
| Daiichi Sankyo INC. | $20.73 | 2024 | Injectafer |
| Emmaus Medical, INC. | $19.75 | 2023 | Endari |
| Hikma Pharmaceuticals USA | $17.60 | 2020 | |
| Circassia INC. | $16.02 | 2019 | |
| Shield Therapeutics INC | $14.40 | 2025 | |
| Adc Therapeutics America, INC. | $13.20 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $12.12 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Dowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.